Arcadia Biosciences (RKDA) Equity Average (2016 - 2025)
Arcadia Biosciences (RKDA) has disclosed Equity Average for 11 consecutive years, with $5.0 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Equity Average fell 54.06% year-over-year to $5.0 million, compared with a TTM value of $5.0 million through Sep 2025, down 54.06%, and an annual FY2024 reading of $9.5 million, down 43.68% over the prior year.
- Equity Average was $5.0 million for Q3 2025 at Arcadia Biosciences, down from $6.7 million in the prior quarter.
- Across five years, Equity Average topped out at $44.2 million in Q2 2021 and bottomed at $5.0 million in Q3 2025.
- Average Equity Average over 5 years is $20.7 million, with a median of $17.2 million recorded in 2023.
- The sharpest move saw Equity Average soared 261.37% in 2021, then tumbled 54.06% in 2025.
- Year by year, Equity Average stood at $35.7 million in 2021, then crashed by 35.7% to $23.0 million in 2022, then crashed by 38.8% to $14.1 million in 2023, then plummeted by 41.74% to $8.2 million in 2024, then plummeted by 39.07% to $5.0 million in 2025.
- Business Quant data shows Equity Average for RKDA at $5.0 million in Q3 2025, $6.7 million in Q2 2025, and $7.6 million in Q1 2025.